Oblenio Bio

Series-B+
obleniobio.com Biotech & Healthcare Oakland, United States 1-10
Total Funding $62M
Latest Round $62M Series-B+
Last Announced Jun 25, 2026
Investors 4 Backers
Decision Makers Profile Active

About Oblenio Bio

Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Oakland, United States
Team Size 1-10
Tracked Since Sep 29, 2026

Web & Domain Identity

Official Website obleniobio.com
Domain Registered Date Nov 28, 2023

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $62,000,000 · Series-B+

    fundraisingfox.com

  2. Milestone

    Website domain registered

    obleniobio.com

Investors & Backers

4
Aditum Bio
Deep Track Capital
GV
Pfizer Venture Investments

Funding History

1 Round
Series-B+ · Jun 25, 2026

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts